Brilanestrant - Genentech
Alternative Names: ARN 810; GDC-0810; RG 6046; RO-7056118Latest Information Update: 05 Nov 2023
At a glance
- Originator Aragon Pharmaceuticals
- Developer Genentech
- Class Antineoplastics; Carboxylic acids; Chlorobenzenes; Fluorobenzenes; Indazoles; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HER2 negative breast cancer
Most Recent Events
- 13 Mar 2020 Genentech terminates a phase II trial in Her2-negative-breast-cancer (Locally recurrent, Metastatic disease) in South Korea, Spain, Netherlands, USA due to sponsor's decision to halt the development of brilanestrant (PO) (NCT01823835)
- 28 Feb 2020 Genentech terminates a phase II trial for Her2-negative-breast-cancer (Metastatic disease) in USA, Spain, Germany, Australia, South Korea, and the UK (NCT02569801)
- 30 Jan 2018 Chemical structure information added